NASDAQ:PTGX Protagonist Therapeutics - PTGX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.46 +0.40 (+2.84%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$14.04▼$14.7650-Day Range$7.36▼$14.0652-Week Range$6.91▼$29.62Volume1.55 million shsAverage Volume995,971 shsMarket Capitalization$711.43 millionP/E RatioN/ADividend YieldN/APrice Target$32.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Protagonist Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside127.1% Upside$32.50 Price TargetShort InterestHealthy4.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.60) to ($3.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector606th out of 1,030 stocksPharmaceutical Preparations Industry307th out of 502 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Protagonist Therapeutics has a forecasted upside of 127.1% from its current price of $14.31.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.66% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 14.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 2.9 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.Search Interest10 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions91.51% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from ($2.60) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Protagonist Therapeutics (NASDAQ:PTGX) StockProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.Read More Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 3.6% Higher January 25, 2023 | finance.yahoo.comProtagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 14, 2023 | finance.yahoo.comAre Investors Undervaluing Protagonist Therapeutics, Inc. (NASDAQ:PTGX) By 50%?December 21, 2022 | finance.yahoo.comProtagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 14, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Protagonist Therapeutics (PTGX)December 5, 2022 | finance.yahoo.comCan Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect?December 1, 2022 | finance.yahoo.comProtagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology SummitFebruary 2, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. November 14, 2022 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Passage Bio (PASG), Privia Health Group (PRVA)November 11, 2022 | finance.yahoo.comHow Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%November 11, 2022 | finance.yahoo.comProtagonist Therapeutics Third Quarter 2022 Earnings: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)November 8, 2022 | finance.yahoo.comProtagonist Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 3, 2022 | finance.yahoo.comProtagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual MeetingNovember 1, 2022 | msn.comProtagonist Closes U.K. Deal on London Film Festival’s ‘Pretty Red Dress’ (EXCLUSIVE)October 31, 2022 | msn.comSarah Michelle Gellar Creates Her Own Halloween Meme with Special 'Female Protagonist' CostumeOctober 30, 2022 | msn.com‘Smile’ Producers Line Up Slasher Horror ‘Clown In A Cornfield’, Protagonist Launches Sales — AFMOctober 12, 2022 | finance.yahoo.comInvestors in Protagonist Therapeutics (NASDAQ:PTGX) have unfortunately lost 74% over the last yearOctober 6, 2022 | marketwatch.comThinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro?October 5, 2022 | finance.yahoo.comDoes Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect?October 2, 2022 | finance.yahoo.com‘Stocks Are Looking Increasingly Cheap,’ Says J.P. Morgan; Here Are 2 Names to ConsiderSeptember 23, 2022 | finance.yahoo.comProtagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?September 15, 2022 | seekingalpha.comPTGX Protagonist Therapeutics, Inc.August 10, 2022 | finance.yahoo.comHow Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%June 4, 2022 | seekingalpha.comMGNI, NRIX and PTGX are among after hour and moversJune 2, 2022 | seekingalpha.comProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022June 1, 2022 | finance.yahoo.comProtagonist Therapeutics to Participate at the Jefferies Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Company Calendar Last Earnings11/08/2022Today2/02/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.50 High Stock Price Forecast$41.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+124.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,550,000.00 Net Margins-291.70% Pretax Margin-369.64% Return on Equity-46.74% Return on Assets-40.38% Debt Debt-to-Equity RatioN/A Current Ratio7.53 Quick Ratio7.53 Sales & Book Value Annual Sales$27.36 million Price / Sales26.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.29 per share Price / Book2.30Miscellaneous Outstanding Shares49,200,000Free Float46,591,000Market Cap$711.43 million OptionableNot Optionable Beta2.11 Key ExecutivesDinesh V. PatelPresident, Chief Executive Officer & DirectorAsif AliChief Financial Officer & Executive Vice PresidentMark L. SmytheVice President-TechnologySamuel R. SaksChief Medical OfficerArturo MolinaChief Medical OfficerKey CompetitorsMorphoSysNASDAQ:MORCogent BiosciencesNASDAQ:COGTSeres TherapeuticsNASDAQ:MCRBEmergent BioSolutionsNYSE:EBSAltimmuneNASDAQ:ALTView All CompetitorsInsiders & InstitutionsZurcher Kantonalbank Zurich Cantonalbank Bought 1,337 shares on 2/1/2023Ownership: 0.017%Gratus Capital LLCBought 12,946 shares on 1/27/2023Ownership: 0.445%Dupont Capital Management CorpBought 13,127 shares on 1/26/2023Ownership: 0.027%Allspring Global Investments Holdings LLCSold 5,784 shares on 1/23/2023Ownership: 0.012%Bank of New York Mellon CorpBought 15,988 shares on 12/8/2022Ownership: 0.321%View All Institutional Transactions PTGX Stock - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price forecast for 2023? 4 analysts have issued 1 year target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $21.00 to $41.00. On average, they predict the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 123.7% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2023? Protagonist Therapeutics' stock was trading at $10.91 at the beginning of 2023. Since then, PTGX shares have increased by 33.2% and is now trading at $14.53. View the best growth stocks for 2023 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.30. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 46.74% and a negative net margin of 291.70%. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Gratus Capital LLC (0.45%), Dupont Capital Management Corp (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel, Harold E Selick and Sarah B Noonberg. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $14.53. How much money does Protagonist Therapeutics make? Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $714.88 million and generates $27.36 million in revenue each year. The company earns $-125,550,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. How many employees does Protagonist Therapeutics have? The company employs 118 workers across the globe. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com. This page (NASDAQ:PTGX) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.